DCTs Demonstrate Tremendous Tenacity

Imagine, for a moment, you are trying to advance to market a possible new way to treat lumbar spinal stenosis. You are eager to get this treatment into market – and the tens of thousands who suffer from this agonizing condition want the same.

But the symptoms of the disease can hinder clinical trial completion, since spinal stenosis can make simple travel arduous. For the prospective trial participant, driving – even riding – to the trial site may be outweighed by the risk of pain and suffering. Patients who opt in can just as quickly opt out, and more than 30% do. Of those dropouts, 38% indicate site visit stress as the determining factor.